Study of AHB-171 in Chronic Hepatitis B Participants

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AHB-171 in participants with chronic hepatitis B (CHB). Study advancement to subsequent parts/cohorts will require satisfactory interim reviews of available cumulative safety data by the Safety Review Committees (SRC), using the safety criteria and review procedures described in the protocol.

Timeline

Start

2026-07-06

Primary completion

2027-10-08

Completion

2028-08-14

Drugs

Indications